
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Integrin β1/ITGB1 CRISPR Activation Plasmid (h) | sc-400097-ACT | 20 µg | $397.00 | |||
Integrin β1/ITGB1 CRISPR Activation Plasmid (h2) | sc-400097-ACT-2 | 20 µg | $397.00 |
ITGB1 encodes integrin β1, a core subunit that heterodimerizes with multiple α integrins to mediate cell–extracellular matrix adhesion and bidirectional signaling. Integrin β1 regulates focal adhesion assembly, actin cytoskeleton remodeling, and mechanotransduction through pathways including FAK/SRC, PI3K–AKT, and Rho GTPases, shaping cell migration, survival, and differentiation. By coordinating adhesion-dependent signaling, ITGB1 contributes to tissue organization, wound repair, and immune cell trafficking. Dysregulated ITGB1 expression or signaling is linked to altered invasiveness and adhesion phenotypes in cancer biology, as well as fibrosis and inflammatory pathologies.
Integrin β1/ITGB1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ITGB1 expression without altering the underlying DNA sequence.
Integrin β1/ITGB1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ITGB1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ITGB1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Integrin β1/ITGB1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ITGB1 locus and enabling the study of Integrin β1/ITGB1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Integrin β1/ITGB1 pathway restoration in tumor cells with silenced or reduced ITGB1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.